Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capivasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 8/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 8/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | LATS1 | O95835 | 2/20 | 1.00 |
| ▸ | PRKCB | P05771 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | PRKACB | P22694 | 2/20 | 1.00 |
| ▸ | GRK2 | P25098 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 2/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 2/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capivasertib SCHEMBL31360985 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL29557103 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL390244 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL391382 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL386620 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL386619 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL390401 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL391567 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL393210 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL21619156 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | claimed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | claimed |
| US-11685953-B2 | Biomarkers and methods of treating cancer | ASTRAZENECA AB (SE) | 2023-06-27 | — | — | US | claimed |
| CN-114601836-B | Application of AKT inhibitor in preparation of medicine for treating breast cancer | 四川大学华西医院 | 2022-12-06 | — | — | CN | claimed |
| EP-2785349-B2 | COMBINATION TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2022-11-09 | — | — | EP | claimed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | claimed |
| CN-114601836-A | Application of AKT inhibitor in treatment of breast cancer | 四川大学华西医院 | 2022-06-10 | — | — | CN | claimed |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | claimed |
| US-9492453-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2016-11-15 | — | — | US | claimed |
| US-9487525-B2 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide | ASTRAZENECA AB (SE) | 2016-11-08 | — | — | US | claimed |
| US-20160317540-A1 | Therapeutic Treatment | ASTRAZENECA AB (SE) | 2016-11-03 | — | — | US | claimed |
| US-9402847-B2 | Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide | ASTRAZENECA AB (SE) | 2016-08-02 | — | — | US | claimed |
| US-20150182531-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2015-07-02 | — | — | US | claimed |
| US-20150087661-A1 | Crystalline Forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide | ASTRAZENECA AB (SE) | 2015-03-26 | — | — | US | claimed |
| EP-2201012-B1 | PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2014-06-25 | — | — | EP | claimed |
| US-20140121227-A1 | THERAPEUTIC TREATMENT | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | claimed |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2012-07-26 | — | — | US | claimed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 26/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 26/4885 |
| US-20160317540-A1 | Therapeutic Treatment | TUBA1C, TUBA3C, TUBB1 | AKT1 2345/4885AKT2 3313/4885AKT3 3412/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | AKT1 3945/4885AKT2 4183/4885AKT3 4012/4885 |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885AKT2 335/4885AKT3 257/4885 |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885AKT2 6/4885AKT3 16/4885 |
| US-20150182531-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885AKT2 6/4885AKT3 16/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 26/4885 |
| US-20140121227-A1 | THERAPEUTIC TREATMENT | TUBA1C, TUBA3C, TUBB1 | AKT1 2422/4885AKT2 3383/4885AKT3 3475/4885 |
| US-20150087661-A1 | Crystalline Forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SFPQ, CPS1 | AKT1 4598/4885AKT2 4338/4885AKT3 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.